Comparative cost-effectiveness analysis of oral triptan therapy for migraine in four European countries

[1] Shrank WH(2006)Physicians’ perceptions of relevant prescription drug costs: do costs to the individual patient or to the population matter most? Am. J. Manag. Care 12 545-551

[2] Joseph GJ(1992)Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors JAMA 267 64-69

[3] Choudhry NK(1998)The economic burden of migraine to society Pharmacoeconomics 13 667-676

[4] Young HN(2007)The burden of headache in a patient population from a specialized headache centre Cephalalgia 27 263-270

[5] Ettner SL(2005)An introduction to the basic principles of health economics for those involved in the development and delivery of headache care Cephalalgia 25 709-714

[6] Glassman P(2012)The economic cost of brain disorders in Europe Eur. J. Neurol. 19 155-162

[7] Asch SM(2005)The cost of migraine and its treatment Am. J. Manag. Care 11 S62-S67

[8] Kravitz RL(2008)Impact of headache in Europe: a review for the Eurolight project J. Headache Pain 9 139-146

[9] Stewart WF(2007)The global burden of headache: a documentation of headache prevalence and disability worldwide Cephalalgia 27 193-210

[10] Lipton RB(2010)Triptans for the management of migraine Drugs 70 1505-1518

[1] Shrank WH(2006)Physicians’ perceptions of relevant prescription drug costs: do costs to the individual patient or to the population matter most? Am. J. Manag. Care 12 545-551

[2] Joseph GJ(1992)Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors JAMA 267 64-69

[3] Choudhry NK(1998)The economic burden of migraine to society Pharmacoeconomics 13 667-676

[4] Young HN(2007)The burden of headache in a patient population from a specialized headache centre Cephalalgia 27 263-270

[5] Ettner SL(2005)An introduction to the basic principles of health economics for those involved in the development and delivery of headache care Cephalalgia 25 709-714

[6] Glassman P(2012)The economic cost of brain disorders in Europe Eur. J. Neurol. 19 155-162

[7] Asch SM(2005)The cost of migraine and its treatment Am. J. Manag. Care 11 S62-S67

[8] Kravitz RL(2008)Impact of headache in Europe: a review for the Eurolight project J. Headache Pain 9 139-146

[9] Stewart WF(2007)The global burden of headache: a documentation of headache prevalence and disability worldwide Cephalalgia 27 193-210

[10] Lipton RB(2010)Triptans for the management of migraine Drugs 70 1505-1518